DDInter658 DDInter1376
Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Eprosartan {u} (Compound) resembles {v} (Compound) Losartan
Eprosartan {u} (Compound) treats {v} (Disease) hypertension
Eprosartan {u} (Compound) binds {v} (Gene) CYP2C9
Eprosartan {u} (Compound) upregulates {v} (Gene) GPER1
Eprosartan {u} (Compound) is included by {v} (Pharmacologic Class) Angiotensin 2 Receptor Antagonists
Eprosartan {u} (Compound) downregulates {v} (Gene) KRT18
Eprosartan {u} (Compound) causes {v} (Side Effect) Arthralgia
Eprosartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Eprosartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Eprosartan {u} may lead to a major life threatening interaction when taken with {v} Potassium gluconate
Eprosartan (Compound) resembles Losartan (Compound)
Eprosartan (Compound) treats hypertension (Disease)
Eprosartan (Compound) binds CYP2C9 (Gene)
Eprosartan (Compound) upregulates GPER1 (Gene)
Eprosartan (Compound) is included by Angiotensin 2 Receptor Antagonists (Pharmacologic Class)
Eprosartan (Compound) downregulates KRT18 (Gene)
Eprosartan (Compound) causes Arthralgia (Side Effect)
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine
Eprosartan may lead to a major life threatening interaction when taken with Potassium gluconate